Nav: Home

Suspect cells not guilty after all in late-stage lupus

December 07, 2015

For years, biomedical researchers have suspected that a specific set of immune cells are responsible for causing disease in lupus patients, but until now they haven't known for sure one way or the other.

A Virginia Tech immunologist has found that these cells -- called plasmacytoid dendritic cells -- do not, in fact, contribute to late-stage lupus in mice. The discovery, published in October in the Journal of Immunology, has implications for the future of lupus research.

Xin Luo, assistant professor of immunology in the Department of Biomedical Sciences and Pathobiology in the Virginia-Maryland College of Veterinary Medicine, and her colleagues built upon earlier research showing that lupus patients have been exposed to interferon alpha, a type of protein released by plasmacytoid dendritic cells -- known as pDCs -- and other immune cells. Lupus is an autoimmune disease that can cause chronic fatigue, joint pain, rash, fever, renal failure, and even death. It affects an estimated 3 million people in the United States.

"The clinical data show that patients with lupus have signatures in their gene expression demonstrating that they have been exposed to this protein," Luo said. "That suggests this protein has a pathogenic effect -- in other words, it can cause disease."

Similarly, patients who take interferon alpha as an anti-cancer drug sometimes develop lupus-like symptoms, further supporting the hypothesis that this protein causes lupus. In 2013, a research group found that removing the pDCs in mice reduced the symptoms of lupus, whereas in 2014, another research group removed these cells from mice in both the early and late stages of the disease.

"When the researchers removed the cell type early in the disease, they found that it was really strong at disease attenuation, but in studying this phenomenon further, we found in our experiments that for some reason mice with late-stage lupus didn't produce interferon alpha at all," Luo said. "We asked ourselves, 'How can these cells be pathogenic if they are not producing this pathogenic protein?' "

Luo and her colleagues used new cell-sorting technology to isolate pDCs at a high purity from the bone marrow in mice and separate them from other cells. They then partnered with researchers at the Biocomplexity Institute of Virginia Tech to study the isolated cells using RNA sequencing. Scientists Robert Settlage, director of the Data Analytics Core, and Saikumar Karyala, laboratory manager for the Genomics Research Laboratory, analyzed the samples. Song Li, assistant professor of genomics and bioinformatics in the Department of Crop and Soil Environmental Sciences in the College of Agriculture and Life Sciences, also helped to analyze the data.

"We answered the question that people have been wondering for many years: do these cells actually contribute to disease?" Luo said. "Our data strongly suggests that, in patients who already have lupus, pDCs don't contribute to disease anymore. The damage is already done."

Although pDCs may contribute to lupus five or 10 years before the onset of disease, they are not a factor after lupus symptoms develop. "We believe that these cells are only involved in the initiation of lupus, not the later exacerbation or progression of the disease," Luo explained. "This is very clinically relevant because many researchers are still thinking about targeting pDCs as a treatment for lupus patients, which may not work."

The researchers also found that they can use the same technology to search for early detection biomarkers for lupus. "We can move forward with this set of data to investigate possible early detection and figure out the role of the altered pDCs on lupus," said S. Ansar Ahmed, head of the Department of Biomedical Sciences and Pathobiology and paper co-author. "It's too early to know how these changes are going to affect treatment, but these are the building blocks."
The paper, "Cutting Edge: Plasmacytoid Dendritic Cells in Late-Stage Lupus Mice Defective in Producing IFN-α," was published in the Journal of Immunology's Cutting Edge section, which recognizes a small number of high-impact studies in the field.

The research team also included Xiaofeng Liao, a Ph.D. student in the Department of Biomedical Sciences and Pathobiology; Sha Sun of the Department of Developmental and Cell Biology at the University of California, Irvine; Jingjing Ren, volunteer-turned Ph.D. student in Luo's laboratory; Alex Reihl, a senior majoring in biological sciences in the College of Science; Husen Zhang, assistant professor of civil and environmental engineering in the College of Engineering; and Christopher Reilly, professor and chair for cell and molecular physiology at the Edward Via College of Osteopathic Medicine.

Additional resources are available at Virginia Tech News.

Virginia Tech

Related Lupus Articles:

Studies reveal socioeconomic and racial disparities in lupus
Two new studies have uncovered socioeconomic disparities related to the health of patients with lupus.
Investigating kidney biomarkers to track lupus
To try to better understand how the disease begins and progresses, researchers at the University of Michigan investigated whether kidney biomarkers would signal lupus progression and signs of complications.
Promising new treatment for lupus on the horizon
A drug originally used to boost the immune system is showing promise as a potential new treatment for lupus, Monash University-led research published Aug.
Genetic clue to development of mouth ulcers in lupus
Genetic clue to development of mouth ulcers in lupus
Air pollution exposure may worsen lupus in children
The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) show for the first time that an individual's exposure to air pollution may have a direct role in triggering disease activity as well as airway inflammation in children and adolescents with systemic lupus erythematosus.
Lupus confirmed as risk factor for cervical cancer
Lupus confirmed as risk factor for cervical cancer
Enzyme keeps antibodies from targeting DNA and driving inflammation in lupus
Failure of an enzyme to break down DNA spilling into the bloodstream as cells die may be a major driver of inflammation in lupus.
Abnormal SHP2 signaling contributes to lupus-like symptoms in mice
In this month's issue of the JCI, a research group led by Maria Kontaridis of Harvard University identifies a link between lupus and elevations in SHP2 activity.
Researchers find new clue in lupus autoantibody production
A signaling molecule called interferon gamma could hold the key to understanding how harmful autoantibodies form in lupus patients.
Lupus may contribute to pregnancy-related complications
A new study found that lupus during pregnancy may have negative health impacts for women and their babies.

Related Lupus Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Failure can feel lonely and final. But can we learn from failure, even reframe it, to feel more like a temporary setback? This hour, TED speakers on changing a crushing defeat into a stepping stone. Guests include entrepreneur Leticia Gasca, psychology professor Alison Ledgerwood, astronomer Phil Plait, former professional athlete Charly Haversat, and UPS training manager Jon Bowers.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".